Table 2.
Estimates for 4 Stages of the Human Immunodeficiency Virus Continuum of Care for 2013, by Country
| Country | (1) No. PLHIV (95% CI) | HIV Prevalencea | (2) Diagnosed (Estimated Range)b | (3) Ever on ART (Min, Max Estimate) | (4) Suppressed (Min, Max Estimate) | Suppressed of All PLHIV |
|---|---|---|---|---|---|---|
| Austria | 6500 (6300–6700)c | 0.09% | 88% (86%–91%) | 90% (85%, 94%) | 84% (76%, 91%) | 66% |
| Belgium | 18000 (17700–18300) | 0.19% | 84% (83%–85%) | 96% (96%, 96%) | 82% (77%, 87%) | 66% |
| Denmark | 5500 (5000–6000)d | 0.12% | 91% (83%–100%) | 94% (93%, 94%) | 93% (93%, 93%) | 80% |
| France | 153400 (150600–155900) | 0.29% | 84% (82%–85%) | 93%e | 92%e | 72% |
| Germany | 80000 (69000–91000) | 0.11% | 83% (73%–96%) | 87% (83%, 90%) | 81% (69%, 92%) | 58% |
| Greece | 14200 (13700–14600) | 0.15% | 78% (76%–81%) | 82% (79%, 84%) | 81% (72%, 89%) | 52% |
| Italy | 128100 (122400–133500)f | 0.25% | 90% (86%–94%) | 80% (75%, 85%) | 82% (74%, 90%) | 59% |
| The Netherlands | 22000 (21400–22800) | 0.16% | 85% (82%–88%) | 91% (90%, 92%) | 91% (88%, 94%) | 70% |
| Spain | 140700 (128200–155200) | 0.36% | 82% (78%–86%)g | 76% (73%, 78%) | 81% (72%, 89%) | 50% |
| Sweden | 7000h | 0.09% | 90%h | 92% (92%, 92%) | 93% (93%, 93%) | 77% |
| United Kingdom | 99100 (93000–107400) | 0.19% | 81% (75%–87%)i | 82% (76%, 88%) | 82% (70%, 94%) | 54% |
Percentages shown for stages 2, 3, and 4 are out of the previous stage. Percentages in the final column are calculated out of the total PLHIV (1). Estimates were constructed using standardized methods and may differ from previously published results and official national statistics due to differences in data sources, definitions, and time periods [20–24].
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; PLHIV, people living with human immunodeficiency virus.
aAdult HIV prevalence was estimated by dividing the number of PLHIV by Eurostat population denominators for adults aged ≥15 years in 2013.
bEstimated ranges for the percentage diagnosed were calculated by dividing the number diagnosed by the upper and lower confidence limits for stage 1 (PLHIV), to reflect the uncertainty in the estimate for stage 1, unless otherwise indicated.
cEstimate for PLHIV generated using Austrian cohort data, which cover approximately 76% of people living with HIV in Austria.
dEstimated range (CI not available), informed by the ECDC Modelling Tool and triangulation with other estimates.
eMinimum estimates are not applicable due to the methodology and data sources used to derive the population in care in France. Upper estimates were used to substitute the (missing) minimum estimates when calculating the combined estimates for the proportion on ART and proportion virally suppressed in the 11 European Union countries.
fRange for PLHIV in Italy calculated using the 95% CI for the undiagnosed estimate and, separately, a range of uncertainty for the number diagnosed and lost from care.
gThe 95% CI, reflecting the uncertainty in estimating the diagnosed population nationally in Spain, using a statistical model.
hSurveillance and survey-based estimate for PLHIV; CIs were therefore not available for the estimate of PLHIV, nor was a range available for the diagnosed estimate. However, in Sweden, the number diagnosed is reliably estimated from the national cohort and surveillance data, for which there is no under- or delayed reporting. Point estimate of 7000 PLHIV used to substitute the (missing) upper and lower limit when calculating the overall range for the percentage diagnosed in the 11 European Union countries combined.
iAbsolute number diagnosed in the United Kingdom is reliably derived from national surveillance data. The range presented reflects the uncertainty in the estimate for stage 1.